Vaccine efficacy and SARS-CoV-2 control in California and U.S. during the session 2020–2026: A modeling study

  title={Vaccine efficacy and SARS-CoV-2 control in California and U.S. during the session 2020–2026: A modeling study},
  author={MD. Shahriar Mahmud and Md. Kamrujjaman and Md. Mashih Ibn Yasin Adan and Md Alamgir Hossain and Md Mizanur Rahman and Md Shahidul Islam and Muhammad Mohebujjaman and Md. Mamun Molla},
  journal={Infectious Disease Modelling},
Background Besides maintaining health precautions, vaccination has been the only prevention from SARS-CoV-2, though no clinically proved 100% effective vaccine has been developed till date. At this stage, to withhold the debris of this pandemic-experts need to know the impact of the vaccine efficacy rates, the threshold level of vaccine effectiveness and how long this pandemic may extent with vaccines that have different efficacy rates. In this article, a mathematical model study has been… Expand


An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine. Expand
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. Expand
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease, and Aside from transient local and systemic reactions, no safety concerns were identified. Expand
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
The safety and immunogenicity of a SARS DNA vaccine in a Phase I human study was well tolerated and produced cellular immune responses and neutralizing antibody in healthy adults. Expand
Evaluation of the United States COVID-19 vaccine allocation strategy
A compartmental disease model that incorporates key elements of the current pandemic including age-varying susceptibility to infection, age- varying clinical fraction, an active case-count dependent social distancing level, and time-variesing infectivity is developed. Expand
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines. Expand
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
A single dose of Ad26.COV2.S protected against symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection and was effective against severe–critical disease, including hospitalization and death, in an international, randomized, double-blind, placebo-controlled, phase 3 trial. Expand
A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial
Assessment of the DNA platform alone and in combination with replication-defective adenoviral vector vaccines, in concert with challenge and immune data from nonhuman primates, will facilitate evaluation and potential licensure of an Ebola virus vaccine under the Animal Rule. Expand
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
This article compares the pharmacology, indications, contraindications, and adverse effects of the Pfizer/BioNTech and Moderna vaccines, which can protect recipients from a SARS-CoV- 2 infection by formation of antibodies and provide immunity against a Sars- coV-2 infection. Expand
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
Gene-based vaccination for the SARS-CoV elicits effective immune responses that generate protective immunity in an animal model, and induces T cell and neutralizing antibody responses, as well as protective immunity, in a mouse model. Expand